



R.G.C.C. - RESEARCH GENETIC CANCER CENTRE S.A.

Assessment of the results:

Patient Name: Mr./Ms. _____	Type of cancer: _____
Physician: Dr _____	Stage: _____

Risk of relapse:

CTC concentration

Measured: **isolated** ___ cells/___ ml, SD +/- 0.3cells

Cut off point <= 5cells/7.5ml

Resistance markers:

MDR1: 45%

MRP: 35%

LRP: 2%

GST: 20%

Metastases/angiogenesis risk related markers

FUNCTION	CLINICAL RISK	MARKERS	RESULTS	OUTCOME
Migration-invasion	HIGH RISK	MMPs	35%	HIGH RISK
		KISS-1-r	-25%	HIGH RISK
		Nm23	-10%	HIGH RISK
Angiogenesis	HIGH RISK	VEGFr	30%	HIGH RISK
		FGFr	25%	HIGH RISK
		PDGFr	35%	HIGH RISK

Proliferation related markers:

MECHANISM	CLINICAL RISK	MARKERS	RESULTS	OUTCOME
Signal transduction pathways	HIGH PROLIFERATIVE SIGNAL	Ras/raf/MEK/Erk1-2	35%	HIGH RISK
		mTOR	20%	HIGH RISK
Growth factor receptors	HIGH PROLIFERATIVE SIGNAL	EGFr	40%	HIGH RISK
		TGF-β1/2	55%	HIGH RISK
		c-erb-B2	normal	LOW RISK
Hormone receptors	HORMONE DEPENDENT	Estrogen Receptor	20%	HIGH RISK
		Progesterone Receptor	10%	HIGH RISK
		NC3R4-A	normal	LOW RISK
		NC3R4-B	normal	LOW RISK
Cell cycle rate	RAPID	P27	15%	LOW RISK
		P16	20%	HIGH RISK
		P53	10%	HIGH RISK

Resistance phenotype markers:

MARKERS	RESULTS	OUTCOME	PHENOTYPE
Dnmt1	normal	LOW RISK	NON RESISTANT
06-methyl-DNA-tran.	normal	LOW RISK	
HAT	normal	LOW RISK	
Histone deacetylase	normal	LOW RISK	

Mr./Ms. _____

Industrial Area of Florina, GR 53100 – Florina, Greece

Tel.: +30 23850 41950, 41951, 41960, 41961, Fax.: +30 23850 41931

Website: www.rgcc-group.com E-mail: papasotiriou.ioannis@rgcc-genlab.com

Day, ___/___/___

Therapeutic options***Conventional cytostatics:***

Non cell cycle depended	S phase of cell cycle				Metaphases
Alkylating agents	Inhibitors of topoisomerase I	Inhibitors of topoisomerase II	antimetabolites	Inhibitors of tubulin polymerization	Spindle poisoning agents
Cyclophosphamide		Epirubicin	5FU Capecitabine		Docetaxel

Targeted therapies

Moab (Monoclonal Antibodies)	SMW (Small Molecular Weight molecule)
	Fulvestrant as inhibitor of estrogen positive proliferative signal. Tamoxifen as inhibitor of estrogen positive feedback. Anastrozol as inhibitor of estrogen synthesis. Exemestane as inhibitor of aromatase enzyme.

Radiotherapy/Hyperthermia sensitivity:

Marker	Result (%)	Clinical outcome per marker	Clinical outcome
HSP90	-30%	SENSITIVE	SENSITIVE
HSP72	-15%	SENSITIVE	
HSP27	-25%	SENSITIVE	

Follow-up options:

YES	✓
NO	

Time interval (when)

After 3 months	After 6 months	After 12 months
✓		

Test for follow-up

ONCOTRAILS							ONCOTRACE	ONCOCOUNT
Breast	Lung	Sarcoma	Colon	GI	Prostate	melanoma		
✓								

Mr./Ms. _____